source
- J&J’s Imaavy gains first-in-class label for warm autoimmune hemolytic anemiaJ&J announced that its monoclonal antibody Imaavy has received a label expansion in the United States. The expanded indication makes Imaavy the first therapy approved specifically for warm autoimm…
- Sentivera secures up to $1.5 billion licensing deal for inflammatory disease candidateSentivera, a biotech startup formed by investors behind Metsera, announced a licensing agreement with Shanghai-listed Haisco Pharmaceutical. Under the deal, Sentivera will pay Haisco $40 million u…